Consensus AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX 11:19:38 2023-12-05 am EST Intraday chart for AbbVie Inc. 5-day change 1st Jan Change
143.56 USD -0.41% +4.37% -10.82%

Evolution of the average Target Price on AbbVie Inc.

Price target over the last 5 years

History : Analyst Recommendations

b65503.JVlkeKbhAtpEFC8bon4xYQSpVlQhI4NM2Dkoe5ZREZ4.cxUrCOqnXa13chxo20YGF1XrORlRdrB-6lVaOtAWd_FSLAsN8dNWrnxuSA~68b615f978b163d25178051632649b66
Raymond James Adjusts Price Target on AbbVie to $181 From $177, Maintains Outperform Rating MT
ANALYST RECOMMENDATIONS : Abbvie, Boeing, IBM, Lululemon Athletica, Meta Platforms...
ANALYST RECOMMENDATIONS : Abbvie, Burberry, Chevron, Cisco, M&S...
Deutsche Bank Initiates Coverage on AbbVie With Hold Rating, $150 Price Target MT
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $193, Maintains Overweight Rating MT
Barclays Upgrades AbbVie to Overweight From Equalweight, Raises Price Target to $170 From $160 MT
ANALYST RECOMMENDATIONS : AbbVie, AMD, Astrazeneca, HSBC, Live Nation...
UBS Adjusts AbbVie Price Target to $150 From $157, Maintains Neutral Rating MT
Morgan Stanley Raises Price Target on AbbVie to $193 From $189, Maintains Overweight Rating MT
Raymond James Initiates AbbVie at Outperform Rating With $177 Price Target MT
William Blair Initiates AbbVie With Market Perform Rating MT
HSBC Initiates AbbVie With Buy Rating, $167 Price Target MT
UBS Adjusts AbbVie Price Target to $157 From $165, Maintains Neutral Rating MT
Guggenheim Adjusts AbbVie's Price Target to $171 From $172, Keeps Buy Rating MT
Wells Fargo Adjusts Price Target on AbbVie to $195 From $200, Maintains Overweight Rating MT
Morgan Stanley Adjusts AbbVie's Price Target to $182 From $181, Keeps Overweight Rating MT
UBS Adjusts AbbVie Price Target to $165 From $152, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on AbbVie to $181 From $178, Maintains Overweight Rating MT
Argus Research Downgrades AbbVie to Hold From Buy MT
Guggenheim Initiates AbbVie at Buy With $172 Price Target MT
Wolfe Research Downgrades AbbVie to Peer Perform From Outperform MT
Morgan Stanley Adjusts Price Target on AbbVie to $178 From $182, Maintains Overweight Rating MT
Atlantic Equities Adjusts AbbVie's Price Target to $154 From $157, Maintains Neutral Rating MT
SVB Securities Upgrades AbbVie to Market Perform From Underperform, Adjusts Price Target to $153 From $135 MT
UBS Adjusts AbbVie's Price Target to $152 From $150, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
144.15USD
Average target price
167.35USD
Spread / Average Target
+16.09%
High Price Target
201USD
Spread / Highest target
+39.44%
Low Price Target
126USD
Spread / Lowest Target
-12.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AbbVie Inc.

Raymond James
Deutsche Bank Securities
Morgan Stanley
Barclays
UBS
William Blair & Co.
HSBC
Guggenheim
Wells Fargo Securities
Argus
Wolfe Research
Piper Sandler
Atlantic Equities
SVB Securities LLC
BMO Capital
Truist Securities
Credit Suisse
Societe Generale
Goldman Sachs
Berenberg Bank
JPMorgan Chase
Cowen
Redburn
Mizuho Securities
SVB Leerink
Daiwa Securities
RBC Capital Markets
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer